Plasminogen for use in treating and preventing lung dysfunction
AssigneePrevipharma Consulting GmbH
InventorsStephan T. Kiessig, Ricarda Welz, Elena Willig
Life of this patent
Estimating the term…
Abstract
The present invention relates to plasminogen for use in a method for treating or preventing lung dysfunction associated with the formation of hyaline membranes in a patient, wherein the patient is preferably further administered with at least one plasminogen activator.
Claims24
A method for treating or preventing lung dysfunction in a patient with formed hyaline membranes, wherein the patient with formed hyaline membranes is administered with sufficient amounts of Glu-plasminogen by inhalation.
The method of 1, wherein the lung dysfunction associated with the formation of hyaline membranes is respiratory distress syndrome (RDS) including acute respiratory distress syndrome (ARDS), infant respiratory distress syndrome (IRDS), surfactant deficiency disorder (SDD), or hyaline membrane disease (HMD).
Dependencies are inferred from the claim text.